Kitov Pharmaceuticals has announced that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT 302 (celecoxib...
Gilead Sciences, Inc. announced that the Phase III ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis.
The FDA has granted 510(k) clearance to InBios� DENV Detect NS1 Elisa Kit, used for detection of the dengue virus...
Alvesco is indicated in treatment to control persistent asthma in adults and adolescents (12 years and older).
Combisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β 2 agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short- acting β 2 agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting β 2 agonist
Regular treatment of persistent asthma. Note: budesonide is not intended to be used as a reliever of acute asthma.
Deciphera Pharmaceuticals, Inc. announced that Nature Medicine has published results from a circulating tumor DNA (ctDNA) analysis of the INTRIGUE Phase III study of Qinlock (ripretinib) in GIST patients with mutations in KIT exon 11 and 17/18 only previously treated with imatinib.